Skip to main content
. 2020 Aug 24;10:14128. doi: 10.1038/s41598-020-70726-3

Figure 2.

Figure 2

In-vitro percentage cumulative drug release profile from calcium sulphate hemihydrate (CSH)/nanohydroxyapatite (nHAP) based nanocement (NC) for 12 weeks. (a) RFP release from NC containing RFP (NC + RFP), (b) RFP release from NC containing RFP and INH (NC + RFP + INH), (c) INH release from NC containing INH (NC + INH), (d) INH release from NC containing RFP and INH (NC + RFP + INH), (e) RFP and INH release pattern from NC containing RFP and INH (NC + RFP + INH). (f) Concentration of RFP released at 4, 8 and 12 week from NC containing RFP (NC + RFP). NC1 = CSH:nHAP (80:20), NC2 = CSH:nHAP (60:40), NC3 = CSH:nHAP (40:60).